Last reviewed · How we verify

Gallogen (TOCAMPHYL)

Phase 2 active Small molecule ✓ Verified May 2026

Gallogen (generic name: TOCAMPHYL) is a tocamphyl drug. It is currently in Phase 2 development.

Gallogen works by interacting with a specific biological pathway, although the exact details of this interaction are unclear.

Gallogen is a small molecule with the synonyms TOCAMPHYL, TOCAMPHYL, and TOCANFILO. It has been studied in clinical trials for various conditions, including HPV infection, colorectal cancer, colon cancer, metabolic syndrome, and diet habits, often in combination with other substances such as ellagic acid and Annona muricata.

Likelihood of approval
15.3% vs 15.3% industry baseline
If approved by FDA: likely 2031–2034
Steps remaining: Phase 3 → NDA/BLA submission
Confidence: Medium
Why this estimate
  • Baseline phase 2 → approval rate +15.3pp
    Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2031–2034
EMA EU 2032–2035 +0.7 yr
MHRA GB 2032–2035 +0.7 yr
Health Canada CA 2032–2036 +0.9 yr
TGA AU 2032–2036 +1.2 yr
PMDA JP 2032–2036 +1.5 yr
NMPA CN 2033–2037 +2.3 yr
MFDS KR 2032–2036 +1.4 yr
CDSCO IN 2032–2037 +1.8 yr
ANVISA BR 2033–2037 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic nameTOCAMPHYL
Drug classtocamphyl
ModalitySmall molecule
Therapeutic areaOther
PhasePhase 2

Mechanism of action

Think of Gallogen like a key that fits into a lock in the body. When it binds to its target, it can either turn the lock on or off, depending on the specific pathway it's interacting with. This can have a range of effects, from blocking a harmful process to triggering a beneficial one.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Gallogen

What is Gallogen?

Gallogen (TOCAMPHYL) is a tocamphyl drug.

How does Gallogen work?

Gallogen works by interacting with a specific biological pathway, although the exact details of this interaction are unclear.

What is the generic name of Gallogen?

TOCAMPHYL is the generic (nonproprietary) name of Gallogen.

What drug class is Gallogen in?

Gallogen belongs to the tocamphyl class. See all tocamphyl drugs at /class/tocamphyl.

What development phase is Gallogen in?

Gallogen is in Phase 2.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing